Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 12, 2022 11:20 ET | Source: BioNTech SE

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union

CHMP recommendation based on favorable data from Omicron-adapted vaccinesThe Omicron BA.4/BA.5 bivalent COVID-19 booster vaccine combines 15-µg of mRNA encoding the wild-type spike protein of...
August 23, 2022 06:45 ET | Source: BioNTech SE

Pfizer und BioNTech geben Update zur Wirksamkeit ihres COVID-19-Impfstoffs bei Kindern von 6 Monaten bis 4 Jahren

Daten einer weiterführenden Analyse mit 34 Fällen, die mindestens sieben Tage nach Verabreichung der primären Impfserie bestehend aus drei Dosen auftraten, zeigen eine Impfstoffwirksamkeit von 73,2 %...
August 23, 2022 06:45 ET | Source: BioNTech SE

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age

Updated analysis from 34 cases occurring at least seven days following a three-dose regimen showed 73.2% vaccine efficacy among children ages 6 months through 4 yearsThe vaccine efficacy remained...
August 22, 2022 10:30 ET | Source: BioNTech SE

Pfizer und BioNTech reichen Antrag für Notfallzulassung eines angepassten bivalenten COVID-19-Impfstoffs für Omikron-Varianten BA.4/BA.5 bei der FDA ein

Die Daten stützen Antrag auf Notfallzulassung einer 30-µg-Auffrischungsdosis eines an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoffs für Personen ab 12 JahrenDie Unternehmen haben die...
August 22, 2022 10:30 ET | Source: BioNTech SE

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine

Data support request for Emergency Use Authorization of a 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and olderCompanies have rapidly...
March 15, 2022 18:00 ET | Source: BioNTech SE

Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults

Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among individuals who...
March 08, 2022 12:04 ET | Source: Truveta

Truveta announces new COVID-19 insights and unveils Truveta platform for the first time at #ViVE2022

Bellevue, WASH, March 08, 2022 (GLOBE NEWSWIRE) -- Truveta, the health system-led company with a vision of saving lives with data, unveiled the Truveta platform in its first public demonstration at...
January 25, 2022 06:45 ET | Source: BioNTech SE

Pfizer und BioNTech beginnen klinische Studie zu Omikron-basiertem COVID-19-Impfstoff bei Erwachsenen im Alter von 18-55 Jahren

Die ersten Teilnehmer erhielten im Rahmen der klinischen Studie den Omikron-basierten Impfstoffkandidaten als Impfserie mit zwei Dosen oder als Auffrischungsimpfung NEW YORK und MAINZ, Deutschland,...
January 25, 2022 06:45 ET | Source: BioNTech SE

Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age

First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose NEW YORK and MAINZ, GERMANY, JANUARY 25, 2022 — Pfizer Inc....
December 09, 2021 12:15 ET | Source: BioNTech SE

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older

First emergency use authorization in the United States for a COVID-19 vaccine booster in individuals 16 years and older NEW YORK and MAINZ, Germany, December 9, 2021 — Pfizer Inc. (NYSE: PFE) and...